For example, in a recent study by Choi et al., genetic inhibition of acid sphingomyelinase, which degrades sphingomyelin to ceramide, improved motor impairment and loss of spinal neurons in the FUS-R521C mouse model of ALS, suggesting a role of acid sphingomyelinase as a potentially effective target, and its inhibition was considered a possible therapeutic approach for ALS [150]. The gene discussed is SMPD1; the disease is amyotrophic lateral sclerosis.